Abstract

Human thyroid cancer derived cell lines are widely used to study the mechanisms involved in thyroid carcinogenesis. However, there is limited availability of non-cross-contaminated cancer cell lines derived from papillary thyroid carcinoma (PTC), and the B-CPAP cell line is one of the few such lines. B-CPAP cells have been genetically and cytogenetically well-characterized, but details of their stemness features remain uncertain. Considering that this cell line is extensively used for in vitro studies on thyroid tumorigenesis, we broaden its functional and molecular profiles as well as the tumorigenic capacity. We used functional assays (sphere-forming capacity and efficiency), assessed self-renewal and propagation efficiency and tested in vivo tumorigenicity in Hsd:Athymic Nude-Foxn1nu mice. Expression of markers of stemness, differentiation, and epithelial-mesenchymal transition were estimated at RNA and protein levels in adherent parental cells and sphere-forming cells. Functional aspects and stemness features were compared with normal thyrocytes. Protein expression of xenograft tumors was evaluated by immunohistochemistry. B-CPAP sphere-forming cells were able to form thyrospheres theoretically indefinitely in an appropriate serum-free medium, reverting to the adherent parental cell phenotype when cultured in differentiation medium. Different expression of ALDH1-A1 and CD44 stemness markers and TTF-1 and CK19 differentiation markers allowed discrimination between isolated sphere-forming cells and adherent parental cells, indicating that sphere-forming cells retained stem-like features. In keeping with these observations, tumorigenicity assays confirmed that, relative to parental adherent cells, thyrospheres had enhanced capacity to initiate xenograft tumors. Thyrospheres from normal cell line retained very low functional capacity, as well as different stemness markers expression compared to tumor thyrospheres. Our findings may constitute a useful background to develop an in vitro model for assessing the origin and progression of papillary thyroid carcinoma bearing BRAFV600E and TERT promoter mutations.

Key words: thyrosphere, B-CPAP cell line, TERT mutation, papillary thyroid carcinoma.

Introduction

According to the cancer stem cell hypothesis, tumors are composed of a heterogeneous mixture of cells with distinct proliferative and differentiation capacities [1]. It is thought that only a small subset of these cells, termed cancer stem cells (CSCs), is able to generate new tumors in recipient animals [2]. CSCs possess the capacity of self-renewal, and are responsible for maintaining malignant potential, may acquire migration capacity, and confer resistance to therapy. Several combinations of specific markers and different assays have been used for identifying and isolating CSCs from tumors and tumor cell lines including expression of CD133 and CD44 cell surface markers, the ability to efflux Hoechst 33342 dye, and
ALDEFLUOR assay [3]. Functional approaches, such as evaluation of the capacity to form non-adherent spheres, are also used. Indeed, most CSCs show the ability to propagate nearly indefinitely in vitro without altering their stemness properties [4]. This feature allows for in vitro enrichment of the isolated initial putative stem population [5, 6]. Recently, attention has focused on the possible connection between CSCs and the epithelial-mesenchymal-transition (EMT) process. As epithelial cells undergoing EMT, CSCs downregulate epithelial differentiation markers, such as E-cadherin, which are responsible for the loss of cell-cell adhesion capacity, a pivotal change in the progression of many tumors [7]. The existence of CSCs in papillary thyroid carcinoma (PTC), the most common endocrine malignancy, was postulated approximately ten years ago [8]. However, their presence has been demonstrated only recently [9-12]. The initial lack of information on CSCs in such a common tumor (PTC accounts for approximately 80% of differentiated thyroid carcinoma) [13] is possibly due to difficulties in obtaining suitable surgical material and lack of suitable thyroid-specific enrichment markers capable of discriminating stem-like cells within the heterogeneous tumor mass. The PTC-derived cell line B-CPAP [14, 15] which shares biological features with the primary tumor from which it derives, is one of the few PTC-derived cell lines that is non-cross-contaminated with other cell lines [16]. Because the genetic profile of B-CPAP is considered representative of most aggressive forms of PTC, it is extensively used for studying PTC carcinogenesis [17-20].

Among features that have been described are genetic alterations, such as 
\[BRAF^{V600E}\] and 
\[TP53\] mutations [21], the chromosome profile [14] including the molecular karyotype [22-24], a certain degree of chromosome instability [25], as well as features of epithelial-mesenchymal transition [26]. Nevertheless, functional and molecular studies of putative CSCs have not been extensively reported, as well as the 
\[TERT\] promoter status. Here, we further refined the genotype and broadly dissected the functional and molecular profiles and tumorigenic capacity of B-CPAP cell line.

**Material and Methods**

**Cell lines, sphere culture, and functional assays**

The human B-CPAP papillary thyroid carcinoma-derived cell line (kindly provided by Prof. Fusco, the University Federico II, Naples, Italy) was grown as a monolayer in culture in Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 (DMEM/F12) supplemented with 10% fetal bovine serum (FBS, Life Technologies, Milan, Italy), 2mM L-glutamine and 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich, Milan, Italy), at 37°C in a humidified 5% CO₂ atmosphere.

A sphere-forming assay was used to assess self-renewal and sphere-forming efficiency. For generating thyrospheres, B-CPAP monolayer cells were grown for one week with reduced FBS (5%). Adherent cells were then gently dissociated with StemPro Accutase (Life Technologies), and single cells were cultured in permissive condition, at a density of 2x10⁴ cells/ml in low-attachment flasks (Corning, Corning, NY, USA), in serum-free medium (SFM) as follows: DMEM/F12 with 2% B27 supplement (Life Technologies) and epidermal growth factor (EGF), and basic fibroblastic growth factor (bFGF) (Miltenyi Biotec, Calderara di Reno, BO, Italy) (20 ng/ml each). Monitoring of thyrosphere formation was done with an Olympus IMT-2 inverted microscope (San Diego, CA, USA); images were captured with a Moticam Pro digital camera (Motic, Seneco, MI, Italy).

To confirm self-renewal, primary thyrospheres of approximately 200 μm in size were enzymatically dissociated with StemPro Accutase (Life Technologies) and replated in SFM every seven days at a density of 2x10⁴ cells/ml to obtain next generation spheres.

To evaluate sphere forming efficiency (SFE), thyrospheres were dissociated and seeded at a cell density of 500 cells/ml in low-attachment 24-well plates (Corning) in SFM. Every 15 days, spheres that had formed were counted, dissociated, and replated to generate new spheres. The numbers of spheres counted were expressed as a percent of total plated cells.

To induce differentiation of thyrospheres into adherent cells, thyrospheres were cultured in medium supplemented with 10% FBS for at least 4 weeks, and then harvested for molecular analysis.

Functional parameters and stemness markers of B-CPAP thyrospheres were compared to thyrospheres isolated (see above) from a normal thyrocytes-derived cell line. Nthy-ori 3-1 (SV-40 immortalized normal human thyroid follicular cells) was purchased from Health Protection Agency Culture Collections. Expression of B-CPAP differentiation markers were in preference compared to normal thyroid tissue.

**Reverse Transcription Polymerase Chain Reaction**

Total RNA was extracted from multiple populations including parental cells, various thyrosphere generations, and sphere-derived adherent cells. TRI Reagent Isolation Solution (Sigma-Aldrich) was used according to the
manufacturer’s instructions, and concentration, integrity, and purity were determined by NanoPhotometer™ P300 Version 1.0 (Implen GmbH, München, Germany) for each cell subset.

RNA (1 μg) was reverse transcribed into cDNA using Oligo (dT) 12-18 primers (Life Technologies) and Moloney Murine Leukemia Virus reverse transcriptase (M-MLV; 200 U; Life Technologies) according to the manufacturer’s instructions. cDNA was subsequently amplified by polymerase chain reaction (PCR) according to Lan [27]. Primers and reaction conditions are summarized in Table S1. PCR products were separated by 2% agarose gel electrophoresis, stained with SYBR Safe (Life Technologies), and visualized with a UV transilluminator (ECX-F20M, CSL-MicroDOC-Compact Gel documentation system, Eppendorf, Hamburg, Germany). Signals corresponding to each gene were analyzed using Quantity One software (Bio-Rad Hercules, CA, USA). mRNA amounts were normalized by comparison to GAPDH mRNA levels.

Immunofluorescence staining

For immunostaining, cells from dissociated thyrospheres were replated in SFM on poly-D-lysine coated coverslips for 2 hours before fixation. Cells were fixed with cold methanol for 4 minutes at -20°C for all antibodies, except that cells to be stained for ABCG2 were fixed in 4% paraformaldehyde for 10 minutes at room temperature. Immunostaining was performed as previously described [28] using antibodies listed in Table S2. Alexa-conjugated (Alexa Fluor 488 or 594, Life Technologies) goat anti-mouse or anti-rabbit IgG were used as secondary antibodies. Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI).

Western Blot analysis

Cells were lysed with 2% sodium dodecyl sulfate at 4°C. Protein concentration was measured according to the method of Lowry [29]. Western blot was carried out as previously described [28] using antibodies listed in Table S2. Horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (both from DAKO, Carpinteria, CA, USA) were used as secondary antibodies.

Gene Mutation assay

Genomic DNA was isolated from both adherent cells and primary thyrospheres using a QIAMP DNA Mini Kit (Qiagen, Milan, Italy). Quantification of genomic DNA was determined by NanoPhotometer (Implen).

BRAFV600E mutation

Exon 15 of the BRAF gene was amplified by PCR as previously described [30]. Confirmation of mutation was performed by direct sequencing with an ABI 310 Genetic Analyzer (Applied Biosystems, Milan, Italy) utilizing BigDye ver. 1.1 terminator kit (Applied Biosystems) and specific amplification primers for exon 15 (Life Technologies).

TP53 mutation

Exons 7, 8, and 9 of TP53 were analyzed using primers as previously described [21]. PCR products were amplified with High-Fidelity Taq polymerase (Platinum® Taq DNA Polymerase High Fidelity, Invitrogen), purified (by exonuclease 1 and shrimp alkaline phosphatase) and sequenced by fluorescence-based Sanger’s direct sequencing on an ABI 3130 XL DNA capillary sequencer (Applied Biosystems).

TERT promoter mutation

Standard PCR was carried out for genetic sequencing to identify TERT mutation. Briefly, a fragment of TERT promoter was amplified by PCR on genomic DNA using primers previously described [31]. Thirty nanograms of genomic DNA was used in PCR (initial activation step at 95°C for 3 min, forty cycles of 95°C denaturation for 30 sec, 62°C annealing for 1 min, 72°C elongation for 2.5 min, and a final elongation step at 72°C for 7 min). TERT promoter sequences were generated by direct sequencing with an ABI 310 Genetic Analyzer (Applied Biosystems) utilizing BigDye ver. 1.1 terminator kit (Applied Biosystems).

In vivo tumorigenicity assay

All the experiments involving animals were carried out in accordance with national and European Guidelines for use and care of laboratory animals, according to a protocol approved by the Italian Ministry of Health (268/2012-B). Four to six week-old female Hsd:Athymic Nude-Foxn1nu mice were obtained from Envigo Italy and maintained under specific pathogen-free conditions before xenograft injection. Viability of B-CPAP thyrospheres or adherent cells was evaluated using trypan blue dye exclusion assay before being resuspended in 50% phosphate buffered saline (PBS)-50% Cultrex (Trevigen, Inc., Gaithersburg, MD, USA) solution. The cell suspension (200 µl) was injected subcutaneously into flanks of Hsd:Athymic Nude-Foxn1nu mice (see results). Tumor growth was measured with a caliper once a week for 7 weeks starting from 7 days post injection. Tumor volume was then calculated according to the following formula: V (mm³) = (width² x length)/2. At the end of the experiment, mice were euthanized under anesthesia and tumors were
collected for histological and immunohistochemical analyses. Tumorigenicity efficiency was calculated as percentage of number of tumor formation/total of injection sites.

### Histopathology and Immunohistochemistry

Specimens from tumors were fixed in 10% neutral formalin for 24 hours, and then paraffin embedded. Sections (2 μm) were stained with Hematoxylin & Eosin for morphological evaluation. Specific PTC nuclear features were scanned including clearing, overlapping, grooves, and pseudoinclusions. The architectural pattern (follicular, papillary, solid, sarcomatoid) was evaluated; areas of necrosis and the mitotic index were recorded. Immunohistochemistry (IHC) was performed after heat-mediated antigen retrieval on a Dako autostainer (Glostrup, Denmark) using specific antibodies listed in Table S2.

### Statistical analysis

Results were analyzed using the 2-tailed Student t-test; \( P<0.05 \) was considered statistically significant. Statistical analysis was carried out with Prism, 5.00 software (GraphPad Software, Inc, La Jolla, CA).

### Results

#### Functional characterization

##### Primary thyrosphere formation

A subpopulation of adherent B-CPAP parental cells was able to form thyrospheres in SFM. Specifically, cells growing in suspension formed three-dimensional aggregates – spheroid clusters – at day 3. Spheres were visible after five days and reached the maximum size of 150-300 μm after seven days (Figure 1A). The same behavior was observed for Nthy ori 3-1-derived spheres.

##### Self-renewal

To assess the presence of a self-renewing population of stem-like cells within thyrospheres, primary thyrospheres were enzymatically dissociated and re-seeded at the initial cell density. These cells were found to form secondary spheres. B-CPAP cells had an extensive capacity for self-renewal, reaching at least 21 generations (Figure 1B). The Nthy ori 3-1 self-renewal capacity was instead limited to four generations (Supplement Figure 1A).

##### Sphere-Forming Efficiency (SFE)

B-CPAP adherent cells had an initial SFE of approximately 2%. This value increased with each iteration, reaching a peak value at generation 8 (18%±2.1). Although SFE decreased after generation 8, cells maintained a stable efficiency of 10% through the end of the experiment (20th generation) (Figure 1C). The Nthy ori 3-1 thyrosphere SFE was initially high. However, it diminished from the second sphere generation, by which cells start to flat adhering to the flask surface and gaining epithelial-like morphology in not permissive medium (Supplement Figure 1B).

##### Thyrosphere differentiation

When B-CPAP thyrospheres were cultured in permissive condition, cells from the outermost layer began flattening and attached to the flask surface usually within 24 h after seeding. By 72 h they had acquired an epithelial-like morphology and were indistinguishable from the adherent parental cells (Figure 1D). We refer to these cells as adherent sphere-derived cells.

#### Molecular characterization

The B-CPAP molecular profiles are summarized in Table 1 and are as follows.

### Reverse Transcription-PCR (RT-PCR)

The expression of stem cell markers (Oct4, Nanog, ABCG2, p63, and ALDH1-A1) and thyroid differentiation markers (Tg, PAX8, and TTF-1) were evaluated by RT-PCR, and were compared among parental adherent cells, thyrospheres, and adherent sphere-derived cells to determine the effect of SFM on expression of stemness/differentiation genes.

### Table 1. Molecular profile of B-CPAP cell subsets

|                      | adhP  | thyS | adhSD |
|----------------------|-------|------|-------|
| **Stemness markers** |       |      |       |
| Oct4                 | Pos   | pos  | pos   |
| Nanog                | Pos   | pos  | pos   |
| ABCG2                | Pos   | pos  | pos   |
| ALDH1-A1             | Neg   | pos  | neg   |
| CD44                 | Pos   | pos* | pos   |
| p63                  | Pos   | pos  | pos   |
| **Differentiation markers** |   |      |       |
| TG                   | Neg   | neg  | neg   |
| TTF-1                | Pos   | neg  | pos   |
| PAX8                 | Pos   | pos  | pos   |
| CK19                 | Pos   | neg  | pos   |
| E-cadherin           | Neg   | neg  | neg   |
| Vimentin             | Pos   | pos  | pos   |
| **Specific thyroid somatic mutations** |   |      |       |
| BRAP/VE1             | Pos   | pos  | Pos   |
| p53                  | Pos   | pos  | Pos   |
| TERT                 | Pos   | pos  | Pos   |

adhP: adherent parental cells (monolayer culture); adhSD: adherent Spheres-Derived cells; EMT: epithelial mesenchymal transition; thyS: thyrospheres. *Significantly higher expression compared to adhP and adhSD \( (p=0.007 \) and \( p=0.0246 \), respectively).
Oct4, Nanog, ABCG2, and p63 mRNAs were expressed at comparable levels in all cell subsets; ALDH1-A1 mRNA was expressed in thyrospheres, although it was significantly reduced in adherent parental (p=0.0020) and sphere-derived (p=0.0016) cells (Figure 2A).

Thyroglobulin (Tg) expression was negative; PAX8 was equally expressed in all subsets, and TTF-1 exhibited lower expression in thyrospheres compared to adherent parental cells (p=0.0109) and adherent sphere-derived cells (p=0.0056) (Figure 2B).

No significant difference in mRNA expression through thyrosphere generations was observed; therefore, immunofluorescence and Western-blot analyses were performed on first generation thyrospheres.

All stemness markers but p63 and ALDH1-A1 were expressed in Nthy orí 3-1 thyrospheres, confirming that ALDH1-A1 was specific of B-CPAP thyrospheres (Supplement Figure 2A).

Normal thyroid tissue expressed TTF1, PAX8 and Tg (Supplement Figure 2B).

Immunofluorescence

Thyrospheres were positive for the stem cell marker ALDH1-A1, whereas, TTF-1 differentiation
marker was not detectable. In contrast, both adherent parental and adherent sphere-derived cells were clearly labeled for TTF-1, although neither showed immunoreactivity for ALDH1-A1. The other tested stem-related markers CD44, ABCG2, and Oct4 were expressed by all cell populations. The expression of two EMT markers, E-cadherin and vimentin, was evaluated in the different cell populations. All analyzed cell subsets were negative for E-cadherin but were positive for vimentin expression, which was more pronounced in thyrospheres (Figures 3A-F).

**Western Blot**

Immunoblot analysis confirmed results obtained by RT-PCR and immunofluorescence. ALDH1-A1 protein was expressed exclusively in thyrospheres, whereas, CD44 was present in all cell subsets, although higher expression was observed in thyrospheres compared to adherent parental (p=0.007) and adherent sphere-derived (p=0.0246) cells. p63 was expressed in all cell subsets. In particular, we observed only a 70 kDa band, corresponding to the ΔNp63alpha isoform (Figure 4A). TTF-1 transcription factor and the differentiation marker CK19 were detected only in adherent parental and adherent sphere-derived cells, thyroglobulin was absent in all cell populations, whereas normal thyroid tissue expressed TTF1, CK19 and Tg (Figure 4B).

Moreover, all B-CPAP cell populations were negative for E-cadherin. Vimentin expression was higher in thyrospheres compared to adherent cell populations although the difference was not statistically significant (Figure 4C).

**TERT promoter, BRAF, and TP53 mutations.** Both B-CPAP adherent cells and thyrospheres bore TERT C228T, BRAFV600E, and TP53 mutations.

**Tumorigenicity**

The ability of B-CPAP thyrospheres to induce tumor formation in immunocompromised mice was compared to that of the corresponding adherent cells. Thyrosphere cells were more efficient in inducing tumors when subcutaneously xenografted in Hsd:Athymic Nude-Foxn1nu mice as compared to adherent cells. When thyrosphere cells and adherent cells were inoculated at the same concentration (5x10^5 cells in 200 µl of volume injection) tumor formation was observed in 4 of 6 (66.67%) mice compared to 3 of 8 (37.50%) mice, respectively. Adherent cells remained less efficient (3 tumors out of 8 injections) when they were inoculated at increased concentration (2x10^6 cells in 200µl of volume injection) (Figure 5A and B), suggesting that B-CPAP thyrospheres were more prone to establish tumors in vivo as compared to B-CPAP parental cells. No significant differences in volume were found between adherent cell-derived and thyrosphere cell-derived tumors over seven weeks.

Morphological analysis of tumor masses of tumors derived from B-CPAP adherent parental cells did not exhibit classic PTC-like nuclear features. Tumors were composed of clusters of cells arranged in solid areas, without specific architectural patterns such as follicular or papillary structures. Necrosis was present. A high power field (HPF) evidenced nuclei with severe atypia, hyperchromasia, nuclear membrane irregularities, and pleomorphism. Frequent mitoses were easily found (2-3x10 HPF). Tumors derived from thyrospheres showed similar features, being composed of solid neoplasms with clear-cut malignant features such as angioinvasion. Coagulative necrosis and focal sarcomatoid-storiform areas were evident. IHC analysis indicated the absence of well-differentiated thyroid tumors markers like TTF-1 and Thyroglobulin. Moreover, CK19, HBME1, and p63 (anti-p-40) were negative. Focal reactivity for Galectin-3 was observed, and tumors exhibited a high proliferative index (Mib-1 30-40%) (Figure 5C).
Figure 3. Immunofluorescence pattern in B-CPAP. A) ALDH1-A1 (green) positive thyrospheres and negative adherent cells B) CD44 (green) positive cells in all analyzed subsets, with thyrosphere cells showing brighter immunostaining. C) ABCG2 (red) expression in analyzed subsets. D) Oct4 (red) expression in analyzed cell subsets. E) TTF-1 (red) expression in analyzed subsets. F) Vimentin (positive, green)/E-cadherin (negative) double staining in analyzed cell subsets. Nuclei are stained with DAPI (blue). Scale bar: 20 µm. Images are representative of three independent experiments. Adherent parental cells: adhP; Sphere-Derived cells: adhSD; thyrospheres: thyS. * p<0.05; ** p<0.01.
Figure 4. B-CPAP Western blot analysis A) ALDH1-A1, CD44, and ΔNP63alpha expression in adherent parental cells, adherent Sphere-Derived cells, and thyrospheres (left). Histogram showing expression relative to GAPDH (right). (Data represent the means ± SD of three independent experiments). B) Expression of Tg, TTF-1 and CK19. C) Expression of E-cadherin and vimentin. Controls: fetal liver (ALDH1-A1 and CD44), fetal brain (ΔNP63alpha); normal thyroid (Tg, CK19, TTF-1, E-cadherin and GAPDH). Adherent parental cells: adhP; adherent Sphere-Derived cells: adhSD; thyrospheres: thyS. * p<0.05; **p<0.01.

Discussion

Despite the recognition that CSCs are present in differentiated primary thyroid tumors [9-11] the contributions of CSCs to generating PTC are poorly investigated. Among the various possible experimental models, human cancer cell lines are frequently used. However, few non cross-contaminated PTC-derived cell lines are available for in vitro studies [16], and those that exist are not fully characterized. Considering this, we widened the characterization of B-CPAP, one of the most used PTC-derived cell lines, by refining the genetic profile, defining functional aspects and identifying specific biomarkers that allow discrimination between isolated sphere-forming cells (thyrospheres) and parental adherent cells. Moreover, we compared tumorigenicity of the two populations. We isolated cells with thyrosphere-forming capacity from adherent parental cells, and demonstrated that B-CPAP cells have a higher proliferative potential, culminating in the acquisition of putative indefinite self-renewal capacity, then normal thyrocytes. This difference is in agreement with recent data comparing functional aspects of thyrospheres from normal and tumor thyroid tissue [32, 33]. In our hands, stimulation with EGF and bFGF molecules for several generations was indeed needed for B-CPAP to reach maximal self-renewal capacity, sustaining long-term proliferation and stable growth. Mutated TP53, which characterizes B-CPAP cells, might favor this behavior. Cicales and coworkers [34] have demonstrated that unperturbed levels of p53 impose asymmetrical division in mammary stem cells, whereas, loss of p53 favors symmetrical division. Moreover, a potential role of the mutated form of p53 on the deregulation of the self-renewal/differentiation program of CSCs has been suggested [35]. In addition, although p63 was equally expressed in adherent and thyrosphere cells, we observed that B-CPAP cells showed only the ΔNP63alpha isoform. ΔNP63alpha is the main isoform in epithelial tissues and is essential for the self-renewal of adult stratified epithelial [36] and glandular structures [37]. As the expression of p63 in thyroid tumors is controversial, the finding of this specific isoform in B-CPAP cells reinforces the idea that ΔNP63alpha might regulate self-renewal of B-CPAP thyrospheres, and possibly has a role in thyroid carcinoma proliferation in general. Recent data on ΔNP63alpha expression in mammary CSCs indicate that ΔNP63alpha promotes self-renewal and expansion [38]. Intriguingly, p63 expression has been detected in thyroid solid cell nests, which may represent a pool of stem cells of the adult thyroid [39].
Figure 5. A) Representative images of xenografted B-CPAP grown as adherent cells (upper images) or as thyrosphere (lower images). B) Percentages of tumor masses after 49 days subcutaneous injection of adherent (adhP) or thyrosphere (thyS) B-CPAP cells. C) Representative pictures of tumors from xenografted B-CPAP grown as adherent cells (upper Hematoxylin-Eosin stained images) or as thyrosphere (lower H&E stained images). Morphological analysis of tumors from adherent cells revealed a high-grade thyroid carcinoma with spread coagulative necrosis (upper left, H&E 20X). Frequent mitoses were present (black circle, 40X). Histology in thyrospheres showed diagnostic features of anaplastic-like carcinoma, too. Angioinvasion was evident (inner left, H&E, 20X). Tumor architecture was solid and sarcomatoid (H&E 20X). Immunohistochemical staining for Mib1 confirmed a high proliferative index (around 30%; 20X), TTF-1 (20X), and squamous marker p63 were negative (20X; positive internal control in mouse skin).

We hypothesize that TP53 mutation and ΔNp63alpha expression might contribute to promoting B-CPAP self-renewal. Among the other tested stemness-related markers, the expression of ALDH1-A1 distinguished putative CSCs from adherent parental cells. ALDH1-A1 is a major ALDH family enzyme involved in the oxidation of retinol to retinoic acid in early stem cell differentiation [40]. Recently, its role as a CSC marker has been reported, as well as its association with poor prognosis in many cancers including lung [41], breast [42], prostate [43], thyroid [9, 44], head and neck [45], and renal [46] cancers. According to our results, papillary thyroid carcinoma can be added to this list. Indeed, this feature was also confirmed by the loss of ALDH1-A1 expression in cells derived from thyrospheres grown under differentiation conditions. Based on these observations, we investigated TERT promoter mutation in both B-CPAP populations and demonstrated TERT C228T mutation. TERT mutation represents a new oncogene in approximately 30% of thyroid cancer [47]. The mutation induces monoallelic activation of the gene [48] and prevents silencing of TERT upon differentiation of stem cells [49].
addition, B-CPAP thyrospheres and parental cells harbored \textit{BRAF}^{V600E} mutation. In line with the aggressiveness of the primary tumor from which B-CPAP has been derived, a synergistic effect of \textit{TERT} promoter mutation in combination with \textit{BRAF}^{V600E} on poor clinicopathologic outcomes of PTC has been recently proposed\cite{50}. Accordingly, we also observed higher expression of CD44 stem marker in thyrospheres than parental cells, lack of expression of TTF-1 and CK19 differentiation markers, downregulation of E-cadherin epithelial marker, and upregulation of vimentin mesenchymal marker. In aggregate, these findings suggested that sphere-forming cells had tumorigenic potential, which was confirmed \textit{in vivo} using immunocompromised mice. Intriguingly, it has been reported that parental B-CPAP cells establish heterotopic tumors in immunocompromised mice\cite{15} at concentrations 6 fold and 1.5 fold higher than the ones we used for testing tumorigenicity of B-CPAP thyrospheres and parental cells, respectively. This suggests that our thyrospheres were enriched for tumor-initiating cells by at least 4 folds compared to parental cells. The IHC analysis of tumor masses confirmed a high proliferation index and absence of classic PTC-markers such as CK19, TTF-1, and HBME1. Lack of these markers is a feature of CSC-rich anaplastic thyroid carcinoma\cite{51}, and it is also in line with enrichment of stem-like cancer cells in thyrospheres. As a whole, the profile of this cell line is consistent with that of cancer stem-like cell populations observed in aggressive papillary thyroid carcinoma\cite{32, 33, 52}.

Conclusions

The B-CPAP cell line, characterized by \textit{TERT} promoter mutation, \textit{BRAF}^{V600E}, and \textit{TP53} mutations, possess a subpopulation of cells with cancer stem-like properties and is capable of forming thyrospheres. Thyrosphere cells have a putative indefinite self-renewal capacity. Compared to adherent cells they are characterized by differential expression of two stemness markers (ALDH1-A1 and CD44) and two differentiation markers (TTF-1 and CK19) and have higher tumorigenic potential. The characterization of sphere-forming cells from the B-CPAP cell line reported here may contribute to the development of a useful \textit{in vitro} model for dissecting the origin and progression of papillary thyroid carcinoma.

Abbreviations

bFGF: basic fibroblastic growth factor; CSCs: cancer stem cells; DAPI: 4’,6-diamidino-2-phenylindole; DMEM/F12: Dulbecco’s Modified Eagle’s Medium/Ham’s F-12; EGF: epidermal growth factor; EMT: epithelial-mesenchymal-transition; FBS: fetal bovine serum; H&E: hematoxylin-eosin; HPF: high power field; IHC: immunohistochemistry; PBS: phosphate buffered saline; PTC: papillary thyroid carcinoma; RT-PCR: reverse transcription polymerase chain reaction; SFE: sphere forming efficiency; SFM: serum-free medium.

Supplementary Material

Supplementary figures and tables.
http://www.jcancer.org/v08p1629s1.pdf

Acknowledgements

Authors are grateful to A. Cappai and L. Moi for mutational analysis, and M. Aliquò and S. Ielapi for technical assistance in the histopathological analysis.

Funding

This work was supported by the program “Projects of national interest (PRIN)” of the Italian Ministry of Education, University and Research (MIUR) grant N. 20122ZF7HE (to R Vanni).

Authors’ Contributions

Authors PC, RP, VS, and RV designed the study and wrote the protocol. Authors PC, RP, DVF, TD, FPani and PZ performed the laboratory experiments. Authors AB, RG, GR, and GR performed the tumorigenicity experiments. Author FPagni performed the histopathological analysis of mouse tumors. All authors contributed to and have approved the final manuscript.

Ethics approval

All procedures and experiments were carried out under approval of the appropriate authorities according to European Directive (63/2010/EU) and Italian law (D.Lgs. 26/2014) on the use of animals for scientific purposes: protocol approved by Italian Ministry of Health N. 268/2012-B. All possible efforts were made to minimize animal pain and discomfort and to reduce the number of experimental subjects.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Islam F, Qiao B, Smith RA, et al. Cancer stem cell: fundamental experimental pathological concepts and updates. Exp Mol Pathol. 2015; 98: 184-91.
2. Hopper GR, Miller BE. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev. 1983; 2: 5-23.
3. Akhbari-Birgani S, Panarjothy T, Zuse A, et al. Cancer stem cells, cancer-initiating cells and methods for their detection. Drug Discov Today. 2016; 21: 836-42.
4. Cao L, Zhou Y, Zhai B, et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011; 11: 71.
carcinoma-derived cell line. Cancer Genet Cytogenet. 2004; 151: 171-7.

14. Sancisi V, Gandolfi G, Ragazzi M, et al. Cadherin 6 Is a New RUNX2 Target in lines derived from papillary thyroid cancer harboring specific gene alterations. Cancer. 2008; 8: 371.

15. Maric I, Viaggi S, Caria P, et al. Centrosomal and mitotic abnormalities in cell cytogenetics of human non-medullary thyroid carcinoma: characterization of Ribeiro FR, Meireles AM, Rocha AS, et al. Conventional and molecular analysis of 40 human thyroid cancer cell lines reveals cross-contamination. Cancer. 2008; 27: 34629-48.

16. Anania M, Gasparri F, Cetti E, et al. Identification of thyroid tumor cell markers and predictor of prostate cancer patients’ outcome. Lab Invest. 2010; 90: 234-44.

17. Liu R, Xu R, TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016; 23: 143-55.

18. Huang FW, Bielski CM, Rinne ML, et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015; 4: e176.

19. Dima M, Pecce V, Biffoni M, et al. Molecular profiles of cancer stem -like cell populations in aggressive thyroid cancers. Endocrine 2016; 53: 145-56

20. Sancisi V, Gandolfi G, Ragazzi M, et al. Cadherin 6 Is a New RUNX2 Target in lines derived from papillary thyroid cancer harboring specific gene alterations. Cancer. 2008; 8: 371.

21. Maric I, Viaggi S, Caria P, et al. Centrosomal and mitotic abnormalities in cell cytogenetics of human non-medullary thyroid carcinoma: characterization of Ribeiro FR, Meireles AM, Rocha AS, et al. Conventional and molecular analysis of 40 human thyroid cancer cell lines reveals cross-contamination. Cancer. 2008; 27: 34629-48.

22. Anania M, Gasparri F, Cetti E, et al. Identification of thyroid tumor cell markers and predictor of prostate cancer patients’ outcome. Lab Invest. 2010; 90: 234-44.

23. Liu R, Xu R, TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016; 23: 143-55.

24. Huang FW, Bielski CM, Rinne ML, et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015; 4: e176.

25. Dima M, Pecce V, Biffoni M, et al. Molecular profiles of cancer stem -like cell populations in aggressive thyroid cancers. Endocrine 2016; 53: 145-56

26. Sancisi V, Gandolfi G, Ragazzi M, et al. Cadherin 6 Is a New RUNX2 Target in lines derived from papillary thyroid cancer harboring specific gene alterations. Cancer. 2008; 8: 371.

27. Maric I, Viaggi S, Caria P, et al. Centrosomal and mitotic abnormalities in cell cytogenetics of human non-medullary thyroid carcinoma: characterization of Ribeiro FR, Meireles AM, Rocha AS, et al. Conventional and molecular analysis of 40 human thyroid cancer cell lines reveals cross-contamination. Cancer. 2008; 27: 34629-48.

28. Anania M, Gasparri F, Cetti E, et al. Identification of thyroid tumor cell markers and predictor of prostate cancer patients’ outcome. Lab Invest. 2010; 90: 234-44.

29. Liu R, Xu R, TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016; 23: 143-55.

30. Huang FW, Bielski CM, Rinne ML, et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015; 4: e176.

31. Dima M, Pecce V, Biffoni M, et al. Molecular profiles of cancer stem -like cell populations in aggressive thyroid cancers. Endocrine 2016; 53: 145-56

32. Sancisi V, Gandolfi G, Ragazzi M, et al. Cadherin 6 Is a New RUNX2 Target in lines derived from papillary thyroid cancer harboring specific gene alterations. Cancer. 2008; 8: 371.

33. Maric I, Viaggi S, Caria P, et al. Centrosomal and mitotic abnormalities in cell cytogenetics of human non-medullary thyroid carcinoma: characterization of Ribeiro FR, Meireles AM, Rocha AS, et al. Conventional and molecular analysis of 40 human thyroid cancer cell lines reveals cross-contamination. Cancer. 2008; 27: 34629-48.

34. Anania M, Gasparri F, Cetti E, et al. Identification of thyroid tumor cell markers and predictor of prostate cancer patients’ outcome. Lab Invest. 2010; 90: 234-44.

35. Liu R, Xu R, TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016; 23: 143-55.

36. Huang FW, Bielski CM, Rinne ML, et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015; 4: e176.

37. Dima M, Pecce V, Biffoni M, et al. Molecular profiles of cancer stem -like cell populations in aggressive thyroid cancers. Endocrine 2016; 53: 145-56

38. Sancisi V, Gandolfi G, Ragazzi M, et al. Cadherin 6 Is a New RUNX2 Target in lines derived from papillary thyroid cancer harboring specific gene alterations. Cancer. 2008; 8: 371.

39. Maric I, Viaggi S, Caria P, et al. Centrosomal and mitotic abnormalities in cell cytogenetics of human non-medullary thyroid carcinoma: characterization of Ribeiro FR, Meireles AM, Rocha AS, et al. Conventional and molecular analysis of 40 human thyroid cancer cell lines reveals cross-contamination. Cancer. 2008; 27: 34629-48.

40. Anania M, Gasparri F, Cetti E, et al. Identification of thyroid tumor cell markers and predictor of prostate cancer patients’ outcome. Lab Invest. 2010; 90: 234-44.

41. Liu R, Xu R, TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016; 23: 143-55.

42. Huang FW, Bielski CM, Rinne ML, et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015; 4: e176.

43. Dima M, Pecce V, Biffoni M, et al. Molecular profiles of cancer stem -like cell populations in aggressive thyroid cancers. Endocrine 2016; 53: 145-56

44. Sancisi V, Gandolfi G, Ragazzi M, et al. Cadherin 6 Is a New RUNX2 Target in lines derived from papillary thyroid cancer harboring specific gene alterations. Cancer. 2008; 8: 371.

45. Maric I, Viaggi S, Caria P, et al. Centrosomal and mitotic abnormalities in cell cytogenetics of human non-medullary thyroid carcinoma: characterization of Ribeiro FR, Meireles AM, Rocha AS, et al. Conventional and molecular analysis of 40 human thyroid cancer cell lines reveals cross-contamination. Cancer. 2008; 27: 34629-48.